• Myeloma UK
  • Clinical Service Excellence Programme
Myeloma Academy
Sign inRegister
Menu
  • Home
  • CPD & Learning
    • Myeloma Nurse Learning Programme
    • My CPD Portfolio
    • Challenging Cases
    • Close
  • Library
    • Guidelines
      • Complications
      • COVID-19 guidance
      • General haemato/oncology
      • Imaging & Analysis
      • Management & Treatment
      • Palliative Care
      • Presentation & Diagnosis
      • Related conditions
      • Close
    • Patient Support and Information
    • Medical animations
    • Remote consultation video
    • Close
  • Resources
    • Myeloma Drug Finder
    • Myeloma Trial Finder
    • Assessment tools
    • Myeloma Spotlight
    • Primary care education
    • Secondary care education
    • Myeloma Nurse Guides
    • Myeloma health economic model
    • Laboratory Practice
    • Close
  • News & Events
    • News
    • Event calendar
    • Meeting highlights
    • Close
  • CSEP
  • About Us
    • Contact Us
    • Close
Menu back  
 

Diagnostic tests and prognostic indicators

IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay.
Djidjik R et al. Pathol Biol (Paris). 2015 Aug 17. pii: S0369-8114(15)00057-7. doi: 10.1016/j.patbio.2015.06.002. [Epub ahead of print].

Patient dose evaluation for the whole-body low-dose multidetector CT (WBLDMDCT) skeleton study in multiple myeloma (MM).
Cretti F et al. Radiol Med. 2015 Aug 19. [Epub ahead of print].

Clinical and prognostic significance of bone marrow abnormalities in the appendicular skeleton detected by low-dose whole-body multidetector computed tomography in patients with multiple myeloma.
Nishida Y et al. Blood Cancer J. 2015 Jul 31;5:e329. doi: 10.1038/bcj.2015.57.

Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates.
Cogbill CH et al. Int J Lab Hematol. 2015 Jul 30. doi: 10.1111/ijlh.12411. [Epub ahead of print].

Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.
Romano A et al. Ann Hematol. 2015 Jul 31. [Epub ahead of print].

  • Guidelines
  • Patient Support and Information
  • Medical animations
  • Remote consultation video
Bottom menu

Charity No. SC 026116
Myeloma UK
22 Logie Mill
Beaverbank Business Park
Edinburgh
EH7 4HG